Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli.
Adjuvants, Pharmaceutic
/ administration & dosage
Administration, Oral
Anti-Bacterial Agents
/ administration & dosage
Benzaldehydes
/ administration & dosage
Biofilms
/ drug effects
Biological Availability
Ciprofloxacin
/ administration & dosage
Computer Simulation
Cymenes
/ administration & dosage
Drug Synergism
Escherichia coli
/ drug effects
Escherichia coli Infections
/ drug therapy
Humans
In Vitro Techniques
Microbial Sensitivity Tests
Staphylococcal Infections
/ drug therapy
Staphylococcus aureus
/ drug effects
Urinary Tract Infections
/ drug therapy
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
04
2020
accepted:
24
04
2020
entrez:
15
5
2020
pubmed:
15
5
2020
medline:
8
8
2020
Statut:
epublish
Résumé
Escherichia coli and Staphylococcus aureus are important agents of urinary tract infections that can often evolve to severe infections. The rise of antibiotic-resistant strains has driven the search for novel therapies to replace the use or act as adjuvants of antibiotics. In this context, plant-derived compounds have been widely investigated. Cuminaldehyde is suggested as the major antimicrobial compound of the cumin seed essential oil. However, this effect is not fully understood. Herein, we investigated the in silico and in vitro activities of cuminaldehyde, as well as its ability to potentiate ciprofloxacin effects against S. aureus and E. coli. In silico analyses were performed by using different computational tools. The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde. For analysis of the possible toxic effects and the theoretical pharmacokinetic parameters of the compound, the Osiris, SwissADME and PROTOX programmes were used. Estimations of cuminaldehyde gastrointestinal absorption, blood brain barrier permeability and skin permeation by using SwissADME; and drug likeness and score by using Osiris, were also evaluated The in vitro antimicrobial effects of cuminaldehyde were determined by using microdilution, biofilm formation and time-kill assays. In silico analysis indicated that cuminaldehyde may act as an antimicrobial and as a membrane permeability enhancer. It was suggested to be highly absorbable by the gastrointestinal tract and likely to cross the blood brain barrier. Also, irritative and harmful effects were predicted for cuminaldehyde if swallowed at its LD50. Good oral bioavailability and drug score were also found for this compound. Cuminaldehyde presented antimicrobial and anti-biofilm effects against S. aureus and E. coli.. When co-incubated with ciprofloxacin, it enhanced the antibiotic antimicrobial and anti-biofilm actions. We suggest that cuminaldehyde may be useful as an adjuvant therapy to ciprofloxacin in S. aureus and E. coli-induced infections.
Identifiants
pubmed: 32407399
doi: 10.1371/journal.pone.0232987
pii: PONE-D-20-10463
pmc: PMC7224478
doi:
Substances chimiques
Adjuvants, Pharmaceutic
0
Anti-Bacterial Agents
0
Benzaldehydes
0
Cymenes
0
Ciprofloxacin
5E8K9I0O4U
cuminaldehyde
O0893NC35F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232987Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8721-E8730
pubmed: 28973850
New Microbiol. 2019 Jan;42(1):21-28
pubmed: 30785206
Diagn Microbiol Infect Dis. 2013 May;76(1):24-30
pubmed: 23537783
Drug Discov Today Technol. 2004 Dec;1(4):337-41
pubmed: 24981612
Pathog Dis. 2014 Apr;70(3):231-9
pubmed: 24453168
Am J Infect Control. 2017 Oct 1;45(10):1101-1105
pubmed: 28629757
Curr Top Microbiol Immunol. 2017;409:263-296
pubmed: 26659121
Pharmacogn Mag. 2010 Jan;6(21):57-61
pubmed: 20548937
BMC Complement Altern Med. 2013 Oct 14;13:265
pubmed: 24119438
BMC Infect Dis. 2015 Nov 25;15:545
pubmed: 26607324
Mol Cell Probes. 2018 Apr;38:25-30
pubmed: 29274826
Phytomedicine. 2017 Dec 15;37:27-48
pubmed: 29174958
Lett Appl Microbiol. 2019 Apr;68(4):313-320
pubmed: 30790318
Arch Microbiol. 2017 Apr;199(3):465-474
pubmed: 27830269
Nat Prod Res. 2008 Mar 20;22(5):428-39
pubmed: 18404563
BMC Infect Dis. 2017 Oct 10;17(1):670
pubmed: 29017466
Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S69-78
pubmed: 26316560
Infect Dis (Lond). 2018 Jan;50(1):52-58
pubmed: 29161942
Pediatr Neonatol. 2018 Feb;59(1):35-41
pubmed: 28642139
PLoS One. 2015 Jul 01;10(7):e0131321
pubmed: 26132146
Front Microbiol. 2016 Dec 21;7:2052
pubmed: 28066373
Pathog Dis. 2016 Jun;74(4):ftw014
pubmed: 26926153
Urol J. 2017 Mar 16;14(2):3028-3034
pubmed: 28299769
J Food Sci. 2010 Mar;75(2):H54-61
pubmed: 20492235
Int J Mol Sci. 2013 Sep 06;14(9):18488-501
pubmed: 24018891
Infection. 2018 Jun;46(3):293-301
pubmed: 29129031
Eur J Clin Microbiol Infect Dis. 2010 Sep;29(9):1095-101
pubmed: 20703891
Curr Top Med Chem. 2018;18(25):2186-2196
pubmed: 30499412
J Food Sci Technol. 2014 May;51(5):957-63
pubmed: 24803704
J Antimicrob Chemother. 2008 Feb;61(2):365-70
pubmed: 18079128
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W53-8
pubmed: 24838562
Ultrason Sonochem. 2019 Sep;56:84-93
pubmed: 31101292
mBio. 2018 Jan 30;9(1):
pubmed: 29382729
Molecules. 2016 Jul 05;21(7):
pubmed: 27399652
Int J Antimicrob Agents. 2018 Dec;52(6):790-798
pubmed: 30145249
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
Iran J Public Health. 2016 Apr;45(4):485-93
pubmed: 27252918
Chem Biodivers. 2015 May;12(5):733-42
pubmed: 26010662
Eur J Pharmacol. 2011 Jul 15;662(1-3):22-30
pubmed: 21554868
Shock. 2017 Jan;47(1S Suppl 1):6-11
pubmed: 27454379
Am J Med. 2002 Jul 8;113 Suppl 1A:45S-54S
pubmed: 12113871
Integr Med Res. 2014 Sep;3(3):133-141
pubmed: 28664089